VaxNewMo is developing next generation conjugate vaccines against bacterial diseases using its patented conjugating enzyme technology. Our conjugating enzyme technology is faster, more natural, and more reliable than methods used by pharmaceutical companies.

For more information, visit VaxNewMo or follow their updates on:

Locations

Financials

  • $3m

VaxNewMo Articles

In 2019, BioGenerator Invested $3.2 Million in 16 Bioscience Companies in St. Louis

mm
EQ Staff, Jonathan Allen
3 Min Read

 844 Views

-
217
Visitors

VaxNewMo’s Vaccine Breakthrough Published in Nature

mm
EQ Staff, Jonathan Allen
2 Min Read

 901 Views

-
138
Visitors

A “No” from Arch Grants Isn’t a “No” to Your Business

mm
Jonathan Allen
6 Min Read

 1,120 Views

-
244
Visitors

Bioscience Startup Founders: Expect Bumps in the Road From Academic to Entrepreneur

mm
Jonathan Allen
4 Min Read

 886 Views

-
142
Visitors

Meet the Next Generation of Job Creators Winning in St. Louis

mm
Jonathan Allen
4 Min Read

 988 Views

-
194
Visitors

18 Startups Win $50,000 Each To Locate Their Business In St Louis

mm
Jonathan Allen
4 Min Read

 1,482 Views

-
316
Visitors